Lupin has received final approval from USFDA for its Omeprazole delayed-release capsules 40 mg which is market equivalent of AstraZeneca Prilosec delayed-release capsules 40mg. The drug is indicated for the short-term treatment of duodenal ulcer, gastric ulcer, treatment of Gastro Esophageal Reflux Disease (GERD), maintenance of healing of erosive esophagitis and pathological hypersecretory conditions.
Company Profile : Lupin Ltd
Leave a Reply